Mon Dec 5 2022 - 08:14
Fusion Antibodies, the Belfast-based contract research firm, made a loss of £1.1 million for the six months to the end of September as it attempts to restructure the business. The company’s latest half-year results show group revenue also fell to £1.9 million, down from £2.4 million for the same period last year, while spending on research and development rose by 7 per cent to £450,000.“We are re-positioning the company’s service offering to best serve our clients in therapeutic antibody drug discovery.”
“Following the restructuring of our commercial team and once again attending in-person conferences this is the right time to re-align our services with client needs,” he said.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: